Announcements Trials
Browse Landscape

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 2929Neoplasms 2624Lung Neoplasms 1366Colorectal Neoplasms 1328Prostatic Neoplasms 1214Carcinoma, Non-Small-Cell Lung 1079Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Ovarian Neoplasms 586Colonic Neoplasms 533Uterine Cervical Neoplasms 497Head and Neck Neoplasms 495Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 404Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 397Urinary Bladder Neoplasms 386Leukemia, Myeloid, Acute 385Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 312Recurrence 298Disease 272

Interventions

enzalutamide 1darolutamide 1apalutamide 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Metastatic Hormone-sensitive Prostate Cancer × Clear all
NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07031258 2025-06-22

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Nanfang Hospital, Southern Medical University

Not yet recruiting
50 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Bayer

Completed
106 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡